NNC 63-0532

From WikiMD's WELLNESSPEDIA

NNC 63-0532‏‎ is a chemical compound that belongs to the class of benzodiazepine drugs. It is a potent and selective agonist for the GABA_A receptor, which is a major inhibitory neurotransmitter receptor in the brain. NNC 63-0532‏‎ has been used in scientific research to study the function and pharmacology of GABA_A receptors.

Chemistry[edit]

NNC 63-0532‏‎ is a benzodiazepine, a class of drugs that are typically characterized by a core benzene ring fused to a diazepine ring. Like other benzodiazepines, NNC 63-0532‏‎ has a heterocyclic structure, meaning it contains atoms of at least two different elements in its rings.

Pharmacology[edit]

NNC 63-0532‏‎ acts as an agonist at the GABA_A receptor, meaning it binds to this receptor and activates it. The GABA_A receptor is an ionotropic receptor that, when activated, allows negatively charged chloride ions to enter the neuron, making it more difficult for the neuron to generate an action potential and thus inhibiting its activity.

Research Use[edit]

Due to its potent and selective action on the GABA_A receptor, NNC 63-0532‏‎ has been used in scientific research to study the function and pharmacology of this receptor. It has been particularly useful in studies investigating the role of GABA_A receptors in anxiety, sleep disorders, and epilepsy.

See Also[edit]

This article is a stub related to chemistry. You can help WikiMD by expanding it!


This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.